KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Receivables (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Receivables data on record, last reported at $912.1 million in Q4 2025.

  • For Q4 2025, Receivables rose 25.39% year-over-year to $912.1 million; the TTM value through Dec 2025 reached $912.1 million, up 25.39%, while the annual FY2025 figure was $912.1 million, 25.39% up from the prior year.
  • Receivables reached $912.1 million in Q4 2025 per EW's latest filing, up from $892.8 million in the prior quarter.
  • Across five years, Receivables topped out at $912.1 million in Q4 2025 and bottomed at $661.4 million in Q3 2022.
  • Average Receivables over 5 years is $767.8 million, with a median of $765.6 million recorded in 2023.
  • The widest YoY moves for Receivables: up 25.39% in 2025, down 14.25% in 2025.
  • A 5-year view of Receivables shows it stood at $664.9 million in 2021, then increased by 5.14% to $699.1 million in 2022, then increased by 18.45% to $828.1 million in 2023, then fell by 12.16% to $727.4 million in 2024, then increased by 25.39% to $912.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $912.1 million in Q4 2025, $892.8 million in Q3 2025, and $902.6 million in Q2 2025.